RALPH NIVEN - 05 Jan 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
05 Jan 2023
Net transactions value
-$54,850
Form type
4
Filing time
09 Jan 2023, 17:00:22 UTC
Previous filing
07 Dec 2022
Next filing
08 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $1,131 +650 +40% $1.74* 2,259 05 Jan 2023 Direct F1
transaction AVTE Common Stock Options Exercise $3,424 +1,600 +71% $2.14* 3,859 05 Jan 2023 Direct F1
transaction AVTE Common Stock Sale $59,404 -2,250 -58% $26.40 1,609 05 Jan 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -450 -2.1% $0.000000 21,408 05 Jan 2023 Common Stock 450 $1.74 Direct F1, F3
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -200 -1.5% $0.000000 13,288 05 Jan 2023 Common Stock 200 $1.74 Direct F1, F4
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -200 -1.3% $0.000000 15,094 05 Jan 2023 Common Stock 200 $2.14 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -650 -1.4% $0.000000 46,008 05 Jan 2023 Common Stock 650 $2.14 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -750 -1.3% $0.000000 55,232 05 Jan 2023 Common Stock 750 $2.14 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.21 to $26.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F4 A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F5 A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
F6 A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
F7 A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.